Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 09, 2022

SELL
$1.74 - $2.4 $15,665 - $21,607
-9,003 Reduced 35.77%
16,167 $28,000
Q3 2021

Nov 12, 2021

BUY
$2.08 - $3.6 $1,374 - $2,379
661 Added 2.7%
25,170 $55,000
Q2 2021

Aug 16, 2021

BUY
$3.36 - $10.56 $26,339 - $82,779
7,839 Added 47.02%
24,509 $86,000
Q1 2021

May 14, 2021

SELL
$9.26 - $14.36 $3,139 - $4,868
-339 Reduced 1.99%
16,670 $164,000
Q4 2020

Feb 16, 2021

BUY
$9.84 - $14.26 $13,175 - $19,094
1,339 Added 8.54%
17,009 $184,000
Q2 2020

Aug 13, 2020

SELL
$8.53 - $25.64 $36,934 - $111,021
-4,330 Reduced 21.65%
15,670 $327,000
Q4 2017

Feb 09, 2018

SELL
$2.85 - $3.95 $57,000 - $79,000
-20,000 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$2.45 - $3.65 $49,000 - $73,000
20,000
20,000 $73,000

Others Institutions Holding ADVM

About Adverum Biotechnologies, Inc.


  • Ticker ADVM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 99,333,600
  • Market Cap $471M
  • Description
  • Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...
More about ADVM
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.